Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus

Drugs in R and D

Volumn 11, Issue 3, 2011, Pages 251-257

  Kereiakes, Dean J ^a   Neutel, Joel M ^b  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Orange County Research Center   (United States)

Author keywords

Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; Type 2 diabetes mellitus

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; OLMESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE CUFF; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUPHORIA; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; YOUNG ADULT;

EID: 80052746916     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11592830-000000000-00000     Document Type: Article

References (26)

1. Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007 Dec 10; 167 (22): 2431-6
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-13
3. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S65-7
4. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug 12; 321 (7258): 412-9
5. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13-61
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
7. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105-87
8. Sega R, Cesana G, Milesi C, et al. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997 Jul; 30 (1 Pt 1): 1-6
9. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003 Jun 12; 348 (24): 2407-15
10. Okano Y, Tochikubo O, Umemura S. Relationship between base blood pressure during sleep and health-related quality of life in healthy adults. J Hum Hypertens 2007 Feb; 21 (2): 135-40
11. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006 Jun 1; 354 (22): 2368-74
12. Chavanu K,Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008 Feb 1; 65 (3): 209-18
13. Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. CurrMed Res Opin 2010 Mar; 26 (3): 721-8
14. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007 Feb; 49 (2 Suppl. 2): S12-154
15. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med 2007 Aug; 120 (8): 713-9
16. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. AmJHealth Syst Pharm 2007 Jun; 64 (12): 1279-83
17. Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) 2008 Sep; 10 (9): 707-13; discussion 714-5
18. Tofe Povedano S, Garcia De La Villa B. 24-Hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich) 2009 Aug; 11 (8): 426-31
19. OngKL, CheungBM,Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008 Mar; 18 (3): 222-9
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352 (9131): 837-53
21. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998 Sep 12; 317 (7160): 703-13
22. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 Feb; 16 (2): 434-44
23. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 Dec 4; 288 (21): 2709-16
24. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-62
25. Sharma AM, Davidson J, Koval S, et al. Telmisartan/ hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007; 6: 28
26. Sowers JR, Neutel JM, Saunders E, et al. Antihypertensive efficacy of irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006 Jul; 8 (7): 470-80